Literature DB >> 28830671

Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.

John Wrangle1, Chrystal M Paulos2, Thomas W Smith3, Michael I Nishimura3, Mark P Rubinstein4.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28830671      PMCID： PMC5589154          DOI： 10.1016/j.ymthe.2017.08.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  17 in total

1.  A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

Authors:  Katarzyna Urbanska; Evripidis Lanitis; Mathilde Poussin; Rachel C Lynn; Brian P Gavin; Sander Kelderman; Jason Yu; Nathalie Scholler; Daniel J Powell
Journal:  Cancer Res       Date:  2012-02-07       Impact factor: 12.701

Review 2.  Development of CAR T cells designed to improve antitumor efficacy and safety.

Authors:  Janneke E Jaspers; Renier J Brentjens
Journal:  Pharmacol Ther       Date:  2017-03-22       Impact factor: 12.310

Review 3.  CAR T-cell therapy of solid tumors.

Authors:  Carmen S M Yong; Valerie Dardalhon; Christel Devaud; Naomi Taylor; Phillip K Darcy; Michael H Kershaw
Journal:  Immunol Cell Biol       Date:  2016-12-22       Impact factor: 5.126

4.  Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.

Authors:  Aaron E Foster; Aruna Mahendravada; Nicholas P Shinners; Wei-Chun Chang; Jeannette Crisostomo; An Lu; Mariam Khalil; Eva Morschl; Joanne L Shaw; Sunandan Saha; MyLinh T Duong; Matthew R Collinson-Pautz; David L Torres; Tania Rodriguez; Tsvetelina Pentcheva-Hoang; J Henri Bayle; Kevin M Slawin; David M Spencer
Journal:  Mol Ther       Date:  2017-07-08       Impact factor: 11.454

Review 5.  Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.

Authors:  Matthias Klinger; Jonathan Benjamin; Roman Kischel; Sabine Stienen; Gerhard Zugmaier
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

Review 6.  The use of endogenous T cells for adoptive transfer.

Authors:  Cassian Yee
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors:  Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151

8.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

9.  Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Authors:  Stephanie L Goff; Mark E Dudley; Deborah E Citrin; Robert P Somerville; John R Wunderlich; David N Danforth; Daniel A Zlott; James C Yang; Richard M Sherry; Udai S Kammula; Christopher A Klebanoff; Marybeth S Hughes; Nicholas P Restifo; Michelle M Langhan; Thomas E Shelton; Lily Lu; Mei Li M Kwong; Sadia Ilyas; Nicholas D Klemen; Eden C Payabyab; Kathleen E Morton; Mary Ann Toomey; Seth M Steinberg; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

10.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.